Skip to main content

Table 2 (A) Effect of AZL treatment on serum lipid profile. B) Atherogenic risk marker and cardiovascular risk indicator.

From: Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage

 

CTRL

STZ

AZL(5 mg/kg/day)

SERUM CHOLESTEROL (mg/dL)

70.3 ± 6.4

165 ± 9.6*

71 ± 5.9#

SERUM TRIGLYCERIDES (mg/dL)

68 ± 7.4

146 ± 12.5*

74 ± 11.3#

HDL (mg/dL)

46 ± 3.5

29 ± 7.1*

48 ± 5.2#

LDL (mg/dL)

34 ± 3.9

66 ± 7.9*

41 ± 5.0#

VLDL (mg/dL)

13.6 ± 3

29.2 ± 5.5*

14.8 ± 5.1#

Total Cholesterol/HDL

1.5 ± 0.2

5.6 ± 0.1*

1.4 ± 0.2#

LDL/HDL

0.7 ± 0.1

2.2 ± 0.1*

0.8 ± 0.1#

  1. Values depict mean ± SE for at least n = 6 animals in each group. * means p < 0.05 compared to control group and # means p < 0.05 compared to STZ diabetic group.